US Patent Issued to NantOmics, NantBio, Nant Holdings IP on Sept. 9 for "Method of characterizing a tumor based on an immune gene expression signature in regulatory T cell (Treg)-enriched tumor samples" (California Inventors)

Posted On: 2025-09-10

ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,412,639, issued on Sept. 9, was assigned to NantOmics LLC (Culver City, Calif.), NantBio Inc. (Culver City, Calif.) and Nant Holdings IP LLC (Culver City, Calif.).

"Method of characterizing a tumor based on an immune gene expression signature in regulatory T cell (Treg)-enriched tumor samples" was invented by Kevin B. Givechian (Irvine, Calif.), Kamil A. Wnuk (Playa Vista, Calif.), Chad Garner (Culver City, Calif.), Stephen Charles Benz (Culver City, Calif.), Hermes J. Garban (Culver City, Calif.), Shahrooz Rabizadeh (Agoura Hills, Calif.), Kayvan Niazi (Culver City, Calif.) and Patrick Soon-Shiong (Culver City, Calif.).

According to the abstract* released by the U.S. Patent & Trade...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

US Patent Issued to NantOmics, NantBio, Nant Holdings IP on Sept. 9 for "Method of characterizing a tumor based on an immune gene expression signature in regulatory T cell (Treg)-enriched tumor samples" (California Inventors)